nodes	percent_of_prediction	percent_of_DWPC	metapath
Esmolol—Respiratory failure—Fludarabine—lymphatic system cancer	0.0104	0.0104	CcSEcCtD
Esmolol—Electrocardiogram abnormal—Mitoxantrone—lymphatic system cancer	0.00929	0.00929	CcSEcCtD
Esmolol—Skin necrosis—Methotrexate—lymphatic system cancer	0.00868	0.00868	CcSEcCtD
Esmolol—Extravasation—Bleomycin—lymphatic system cancer	0.0086	0.0086	CcSEcCtD
Esmolol—Cardiac failure congestive—Fludarabine—lymphatic system cancer	0.00819	0.00819	CcSEcCtD
Esmolol—Speech disorder—Carmustine—lymphatic system cancer	0.00761	0.00761	CcSEcCtD
Esmolol—Cardiac failure—Fludarabine—lymphatic system cancer	0.00761	0.00761	CcSEcCtD
Esmolol—Myocardial ischaemia—Mitoxantrone—lymphatic system cancer	0.00757	0.00757	CcSEcCtD
Esmolol—Extravasation—Carmustine—lymphatic system cancer	0.0075	0.0075	CcSEcCtD
Esmolol—Rales—Methotrexate—lymphatic system cancer	0.00739	0.00739	CcSEcCtD
Esmolol—Wheezing—Bleomycin—lymphatic system cancer	0.00728	0.00728	CcSEcCtD
Esmolol—Bronchospasm—Teniposide—lymphatic system cancer	0.00718	0.00718	CcSEcCtD
Esmolol—Extravasation—Vincristine—lymphatic system cancer	0.00716	0.00716	CcSEcCtD
Esmolol—Skin exfoliation—Bleomycin—lymphatic system cancer	0.00716	0.00716	CcSEcCtD
Esmolol—Thinking abnormal—Carmustine—lymphatic system cancer	0.00715	0.00715	CcSEcCtD
Esmolol—Extravasation—Mitoxantrone—lymphatic system cancer	0.00698	0.00698	CcSEcCtD
Esmolol—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.00638	0.00638	CcSEcCtD
Esmolol—Respiratory failure—Vincristine—lymphatic system cancer	0.00636	0.00636	CcSEcCtD
Esmolol—Sweating increased—Fludarabine—lymphatic system cancer	0.00625	0.00625	CcSEcCtD
Esmolol—Angina pectoris—Fludarabine—lymphatic system cancer	0.00625	0.00625	CcSEcCtD
Esmolol—Skin exfoliation—Carmustine—lymphatic system cancer	0.00625	0.00625	CcSEcCtD
Esmolol—Neuropathy—Carmustine—lymphatic system cancer	0.00615	0.00615	CcSEcCtD
Esmolol—Dysuria—Fludarabine—lymphatic system cancer	0.006	0.006	CcSEcCtD
Esmolol—Neuropathy—Vincristine—lymphatic system cancer	0.00587	0.00587	CcSEcCtD
Esmolol—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00583	0.00583	CcSEcCtD
Esmolol—Abnormal vision—Carmustine—lymphatic system cancer	0.00571	0.00571	CcSEcCtD
Esmolol—Mental disability—Carmustine—lymphatic system cancer	0.00568	0.00568	CcSEcCtD
Esmolol—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.00564	0.00564	CcSEcCtD
Esmolol—Myocardial infarction—Fludarabine—lymphatic system cancer	0.00561	0.00561	CcSEcCtD
Esmolol—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00561	0.00561	CcSEcCtD
Esmolol—Ecchymosis—Mitoxantrone—lymphatic system cancer	0.0055	0.0055	CcSEcCtD
Esmolol—Thrombophlebitis—Carmustine—lymphatic system cancer	0.00549	0.00549	CcSEcCtD
Esmolol—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00547	0.00547	CcSEcCtD
Esmolol—Flushing—Teniposide—lymphatic system cancer	0.00542	0.00542	CcSEcCtD
Esmolol—Anorexia—Mechlorethamine—lymphatic system cancer	0.00537	0.00537	CcSEcCtD
Esmolol—Chills—Teniposide—lymphatic system cancer	0.00524	0.00524	CcSEcCtD
Esmolol—Pharyngitis—Fludarabine—lymphatic system cancer	0.0051	0.0051	CcSEcCtD
Esmolol—Visual impairment—Fludarabine—lymphatic system cancer	0.00495	0.00495	CcSEcCtD
Esmolol—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.0049	0.0049	CcSEcCtD
Esmolol—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.00487	0.00487	CcSEcCtD
Esmolol—Psoriasis—Methotrexate—lymphatic system cancer	0.00482	0.00482	CcSEcCtD
Esmolol—Agitation—Teniposide—lymphatic system cancer	0.00468	0.00468	CcSEcCtD
Esmolol—Bronchospasm—Bleomycin—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Esmolol—Chills—Fludarabine—lymphatic system cancer	0.00461	0.00461	CcSEcCtD
Esmolol—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.00453	0.00453	CcSEcCtD
Esmolol—Chest pain—Teniposide—lymphatic system cancer	0.00433	0.00433	CcSEcCtD
Esmolol—Cardiac arrest—Vincristine—lymphatic system cancer	0.00431	0.00431	CcSEcCtD
Esmolol—Urinary retention—Vincristine—lymphatic system cancer	0.00431	0.00431	CcSEcCtD
Esmolol—Confusional state—Teniposide—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Esmolol—Oedema—Teniposide—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Esmolol—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Esmolol—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Esmolol—Agitation—Fludarabine—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Esmolol—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00401	0.00401	CcSEcCtD
Esmolol—Pruritus—Mechlorethamine—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Esmolol—Pleural effusion—Methotrexate—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Esmolol—Anorexia—Teniposide—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Esmolol—Hypotension—Teniposide—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Esmolol—Convulsion—Fludarabine—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Esmolol—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Esmolol—Dyspnoea—Teniposide—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Esmolol—Confusional state—Fludarabine—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Esmolol—Dysuria—Vincristine—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Esmolol—Oedema—Fludarabine—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Esmolol—Decreased appetite—Teniposide—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Esmolol—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Esmolol—Vomiting—Mechlorethamine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Esmolol—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Esmolol—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Esmolol—Speech disorder—Methotrexate—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Esmolol—Flushing—Bleomycin—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Esmolol—Anorexia—Fludarabine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Esmolol—Extravasation—Methotrexate—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Esmolol—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Esmolol—Myocardial infarction—Vincristine—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Esmolol—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Esmolol—Feeling abnormal—Teniposide—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Esmolol—Drowsiness—Mitoxantrone—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Esmolol—Chills—Bleomycin—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Esmolol—Skin discolouration—Methotrexate—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Esmolol—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Esmolol—Nausea—Mechlorethamine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Esmolol—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Esmolol—Urticaria—Teniposide—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Esmolol—Oliguria—Methotrexate—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Esmolol—Body temperature increased—Teniposide—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Esmolol—Erythema—Bleomycin—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Esmolol—Paraesthesia—Fludarabine—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Esmolol—Dyspnoea—Fludarabine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Esmolol—Dyspepsia—Fludarabine—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Esmolol—Decreased appetite—Fludarabine—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Esmolol—Visual impairment—Carmustine—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Esmolol—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Esmolol—Fatigue—Fludarabine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Esmolol—Inflammation—Methotrexate—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Esmolol—Pain—Fludarabine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Esmolol—Constipation—Fludarabine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Esmolol—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Esmolol—Urinary tract disorder—Vincristine—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Esmolol—Respiratory failure—Methotrexate—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Esmolol—Urethral disorder—Vincristine—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Esmolol—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Esmolol—Flushing—Carmustine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Esmolol—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Esmolol—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Esmolol—Asthenia—Teniposide—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Esmolol—Pruritus—Teniposide—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Esmolol—Cardiac disorder—Vincristine—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Esmolol—Skin exfoliation—Methotrexate—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Esmolol—Body temperature increased—Fludarabine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Esmolol—Mental disorder—Carmustine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Esmolol—Erythema—Carmustine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Esmolol—Angiopathy—Vincristine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Esmolol—Chest pain—Bleomycin—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Esmolol—Mental disorder—Vincristine—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Esmolol—Chills—Mitoxantrone—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Esmolol—Ecchymosis—Methotrexate—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Esmolol—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Esmolol—Confusional state—Bleomycin—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Esmolol—Oedema—Bleomycin—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Esmolol—Erythema—Mitoxantrone—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Esmolol—Vomiting—Teniposide—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Esmolol—Agitation—Carmustine—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Esmolol—Asthenia—Fludarabine—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Esmolol—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Esmolol—Headache—Teniposide—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Esmolol—Pruritus—Fludarabine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Esmolol—Anorexia—Bleomycin—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Esmolol—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Esmolol—Agitation—Vincristine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Esmolol—Hypotension—Bleomycin—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Esmolol—Convulsion—Carmustine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Esmolol—Nausea—Teniposide—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Esmolol—Chest pain—Carmustine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Esmolol—Anxiety—Carmustine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Esmolol—Paraesthesia—Bleomycin—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Esmolol—Dyspnoea—Bleomycin—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Esmolol—Convulsion—Vincristine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Esmolol—Confusional state—Carmustine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Esmolol—Oedema—Carmustine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Esmolol—Decreased appetite—Bleomycin—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Esmolol—Vomiting—Fludarabine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Esmolol—Convulsion—Mitoxantrone—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Esmolol—Pain—Bleomycin—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Esmolol—Headache—Fludarabine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Esmolol—Chest pain—Mitoxantrone—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Esmolol—Anxiety—Mitoxantrone—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Esmolol—Oedema—Vincristine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Esmolol—Anorexia—Carmustine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Esmolol—Feeling abnormal—Bleomycin—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Esmolol—Confusional state—Mitoxantrone—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Esmolol—Nervous system disorder—Vincristine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Esmolol—Hypotension—Carmustine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Esmolol—Oedema—Mitoxantrone—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Esmolol—Nausea—Fludarabine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Esmolol—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Esmolol—Shock—Mitoxantrone—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Esmolol—Urticaria—Bleomycin—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Esmolol—Anorexia—Vincristine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Esmolol—Body temperature increased—Bleomycin—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Esmolol—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Esmolol—Irritability—Methotrexate—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Esmolol—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Esmolol—Paraesthesia—Carmustine—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Esmolol—Hypotension—Vincristine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Esmolol—Dyspnoea—Carmustine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Esmolol—Somnolence—Carmustine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Esmolol—Anorexia—Mitoxantrone—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Esmolol—Decreased appetite—Carmustine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Esmolol—Hypotension—Mitoxantrone—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Esmolol—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Esmolol—Paraesthesia—Vincristine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Esmolol—Pain—Carmustine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Esmolol—Constipation—Carmustine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Esmolol—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Esmolol—Decreased appetite—Vincristine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Esmolol—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Esmolol—Somnolence—Mitoxantrone—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Esmolol—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Esmolol—Feeling abnormal—Carmustine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Esmolol—Fatigue—Vincristine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Esmolol—Asthenia—Bleomycin—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Esmolol—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Esmolol—Constipation—Vincristine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Esmolol—Pain—Vincristine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Esmolol—Pruritus—Bleomycin—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Esmolol—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Esmolol—Fatigue—Mitoxantrone—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Esmolol—Pain—Mitoxantrone—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Esmolol—Constipation—Mitoxantrone—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Esmolol—Body temperature increased—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Esmolol—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Esmolol—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Esmolol—Dysuria—Methotrexate—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Esmolol—Body temperature increased—Vincristine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Esmolol—Urticaria—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Esmolol—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Esmolol—Vomiting—Bleomycin—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Esmolol—Drowsiness—Methotrexate—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Esmolol—Asthenia—Carmustine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Esmolol—Asthenia—Vincristine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Esmolol—Nausea—Bleomycin—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Esmolol—Asthenia—Mitoxantrone—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Esmolol—Dizziness—Carmustine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Esmolol—Pharyngitis—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Esmolol—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Esmolol—Urethral disorder—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Esmolol—Vomiting—Carmustine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Esmolol—Dizziness—Vincristine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Esmolol—Visual impairment—Methotrexate—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Esmolol—Headache—Carmustine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Esmolol—Vomiting—Vincristine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Esmolol—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Esmolol—Headache—Vincristine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Esmolol—Nausea—Carmustine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Esmolol—Angiopathy—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Esmolol—Vomiting—Mitoxantrone—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Esmolol—Chills—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Esmolol—Headache—Mitoxantrone—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Esmolol—Mental disorder—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Esmolol—Erythema—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Esmolol—Nausea—Vincristine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Esmolol—Dysgeusia—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Esmolol—Nausea—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Esmolol—Convulsion—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Esmolol—Chest pain—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Esmolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Esmolol—Confusional state—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Esmolol—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Esmolol—Skin disorder—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Esmolol—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Esmolol—Anorexia—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Esmolol—Hypotension—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Esmolol—Paraesthesia—Methotrexate—lymphatic system cancer	0.000971	0.000971	CcSEcCtD
Esmolol—Dyspnoea—Methotrexate—lymphatic system cancer	0.000964	0.000964	CcSEcCtD
Esmolol—Somnolence—Methotrexate—lymphatic system cancer	0.000962	0.000962	CcSEcCtD
Esmolol—Dyspepsia—Methotrexate—lymphatic system cancer	0.000952	0.000952	CcSEcCtD
Esmolol—Decreased appetite—Methotrexate—lymphatic system cancer	0.00094	0.00094	CcSEcCtD
Esmolol—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000934	0.000934	CcSEcCtD
Esmolol—Fatigue—Methotrexate—lymphatic system cancer	0.000933	0.000933	CcSEcCtD
Esmolol—Pain—Methotrexate—lymphatic system cancer	0.000925	0.000925	CcSEcCtD
Esmolol—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000891	0.000891	CcSEcCtD
Esmolol—Urticaria—Methotrexate—lymphatic system cancer	0.000859	0.000859	CcSEcCtD
Esmolol—Body temperature increased—Methotrexate—lymphatic system cancer	0.000855	0.000855	CcSEcCtD
Esmolol—Asthenia—Methotrexate—lymphatic system cancer	0.000776	0.000776	CcSEcCtD
Esmolol—Pruritus—Methotrexate—lymphatic system cancer	0.000765	0.000765	CcSEcCtD
Esmolol—Dizziness—Methotrexate—lymphatic system cancer	0.000715	0.000715	CcSEcCtD
Esmolol—Vomiting—Methotrexate—lymphatic system cancer	0.000688	0.000688	CcSEcCtD
Esmolol—Headache—Methotrexate—lymphatic system cancer	0.000678	0.000678	CcSEcCtD
Esmolol—Nausea—Methotrexate—lymphatic system cancer	0.000643	0.000643	CcSEcCtD
